North China Pharmaceutical Company Ltd. Class A

North China Pharmaceutical Company Ltd. Class A

SSSE:600812
4.50
CNY
-0.14
(-3.02%)
0.09EPS
95.16P/E
8.54BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
9.11
6.1
4.9
4.9
4.93
5.63
7.05
7.09
6.1
6.12
6.21
5.75
5.4
4.54
Basic EPS, GAAP
0.01
0.03
0.04
0.03
0.01
0.09
0.11
0.06
0.01
-0.4
- -
0.07
0.11
0.05
Free Cash Flow per Basic Share
-0.51
-0.11
-0.15
-0.45
-0.07
0.16
0.06
-0.16
0.3
0.27
0.25
0.26
0.37
- -
Dividend per Share
0.32
0.23
0.25
0.27
0.26
0.32
0.38
0.4
0.44
0.43
0.31
0.27
0.24
0.21
Book Value per Share
2.93
3.19
3.24
3.26
3.25
3.34
3.49
3.76
3.55
3.09
3.1
3.14
3.21
3.22
Tangible Book Value per Share
2.49
2.76
2.74
2.71
2.64
2.54
2.51
2.14
1.82
1.18
0.72
0.46
0.29
0.19
Basic Weighted Avg Shares
1,366
1,541
1,611
1,649
1,563
1,637
1,624
1,622
1,702
1,715
1,630
1,716
1,711
1,709
Sales/Revenue/Turnover
12,438
9,394
7,903
8,082
7,709
9,214
11,457
11,493
10,385
10,500
10,120
9,870
9,242
7,766
Operating Margin (%)
0.99
2.75
3.22
2.96
6.87
7.39
6.92
6.84
6.5
7.41
5.9
7.4
7.2
6.21
Depreciation Expense
345
407
391
420
449
546
581
620
703
779
878
863
945
- -
Net Income, GAAP
14
39
63
54
19
151
172
97
19
-689
5
127
183
89
Effective Tax Rate (%)
60.12
45.42
30.54
33.93
75.76
26.5
36.08
44.03
73.77
- -
68.85
30.62
27.97
33.12
Profit Margin (%)
0.11
0.41
0.8
0.67
0.24
1.64
1.5
0.85
0.18
-6.56
0.05
1.29
1.98
1.15
Working Capital
-1,484
-2,870
-1,364
-2,411
-1,878
-3,348
-2,180
166
-1,528
-3,426
-2,251
-2,702
-4,268
-1,486
LT Debt
3,085
1,491
2,820
1,707
2,475
1,287
2,144
4,899
3,627
2,542
4,380
3,722
2,001
4,666
Total Equity
4,146
5,252
5,270
5,291
5,281
5,512
5,754
7,056
7,017
6,228
6,270
6,675
6,885
6,859
Return on Invested Capital (%)
-0.48
-0.14
0.07
-0.09
0.22
1.26
1.29
0.62
0.18
- -
0.3
1.29
1.49
- -
Return on Capital (%)
0.95
1.94
2.55
2.2
0.92
3.69
3.73
2.35
0.83
- -
0.67
2.01
2.04
- -
Return on Common Equity (%)
0.34
0.83
1.2
1.03
0.35
2.8
3.09
1.65
0.31
-12.11
0.09
2.37
3.36
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
8,260
7,286
6,448
LT Borrowings
2,852
3,549
4,565
LT Finance Leases
125
104
101
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,716
1,716
1,716
Market Capitalization
9,334
7,326
8,544

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
8,265
7,978
8,185
Cash, Cash Equivalents & STI
1,385
1,180
1,509
Accounts Receivable, Net
2,604
2,550
2,437
Inventories
2,413
2,472
2,543
Total Current Liabilities
11,437
10,500
9,670
Payables & Accruals
- -
- -
- -
ST Debt
8,260
7,286
6,448
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.01%
-0.3%
3.15%
Free Cash Flow
-92.4%
-53.05%
42.48%
Net Income, GAAP
-82.59%
-284.17%
44.15%
Sales/Revenue/Turnover
2.08%
-4.2%
-6.36%
Total Cash Common Dividend
1.88%
-7.54%
-11.99%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,558
2,674
2,329
2,309
9,870
2025
2,574
2,701
- -
1,757
9,242
2026
2,153
2,066
1,790
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.03
0.02
0.01
0.07
2025
0.03
0.04
- -
0.01
0.11
2026
0.02
0.02
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
0.07
0.08
0.06
0.27
2025
0.04
0.07
- -
0.05
0.24
2026
0.04
0.08
0.04
- -
- -

Company Description

CEO
Min Zhang
Full Time Employees
9,972
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 388, Heping East Road Shijiazhuang HE China 050015
IPO Date
Jan 14, 1994
Website
ncpc.cn
Business
North China Pharmaceutical Company Ltd (600812.SS) engages in the research, development, production and sales of pharmaceutical products in China and internationally. Founded in 1992 and headquartered in Shijiazhuang, Hebei province, the company offers chemical pharmaceuticals including anti-infectives such as penicillins, cephalosporins, clindamycin phosphate and vancomycin hydrochloride; biotechnology drugs encompassing recombinant human granulocyte colony-stimulating factor, recombinant human erythropoietin biosimilars and recombinant hepatitis B vaccines; cardiovascular and cerebrovascular treatments; immunomodulators; vitamins and nutritional health products like vitamin B6 injections and adenosylcobalamin capsules; biological pesticides; veterinary drugs; and active pharmaceutical ingredients, excipients and finished dosage forms including injections, tablets and powders. It operates primarily in the pharmaceutical industry with over 700 products across anti-infection, cardio-cerebrovascular, anti-tumor, immune regulation, nephropathy and health consumer segments, targeting domestic hospitals, retailers and export markets while maintaining subsidiaries like NCPC Hebei Huamin Pharmaceutical Co Ltd and North China Pharmaceutical Huasheng Co Ltd. Recent developments include securing approvals in 2025 for isavuconazonium sulfate for injection, vitamin B6 injection and other new drugs; obtaining EU GMP certification in March 2025; completing acquisitions of stakes in NCPC Hebei Huamin Pharmaceutical and North China Pharmaceutical Group Aino Co; signing a financial services agreement with Jizhong Energy Group Finance; and announcing its 2025 semi-annual report with operational advancements in biomedicine.